4.78% -0.055

Aytu Biopharma Inc (AYTU)

概要ニュース株価時系列 Financials なぜAYTUが下落しているのか？ディスカッション予測株式分割

Relative Volume:

ネットキャッシュフロー:

Aytu Biopharma Inc Stock (AYTU) Company Profile

Aytu Biopharma Inc

Healthcare (1161)

(720) 437-6580

7900 E. UNION AVENUE, DENVER

@aytubioscience

AYTU's Discussions on Twitter

AYTU を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
AYTU Aytu Biopharma Inc	1.0955	7.10M	93.76M	-13.68M	8.77M	-2.63
ZTS Zoetis Inc	161.34	73.88B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.20	48.17B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.48	47.59B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.07	17.28B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	309.41	13.78B	2.76B	1.11B	898.10M	22.77

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2021-03-30	開始されました	Cantor Fitzgerald	Overweight
2020-05-29	開始されました	H.C. Wainwright	Buy

Aytu Biopharma Inc (AYTU) 最新ニュース

Aytu Biopharma Inc (AYTU) 財務データ

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc Stock (AYTU) Company Profile

AYTU を他の銘柄と比較する

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Aytu Biopharma Inc (AYTU) 最新ニュース

Vascular Ehlers-Danlos Syndrome Market Growth Projections - openPR.com

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer - ACCESS Newswire

AYTU stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia

AYTU BIOSCIENCE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Australia

Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com India

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock By Investing.com - Investing.com South Africa

AYTU BIOPHARMA CEO Acquires 15,000 Shares - TradingView

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - ACCESS Newswire

Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - ACCESS Newswire

Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue - ACCESS Newswire

Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN

AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia

AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa

Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire

Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire

Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com

Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks

Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey

Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks

Aytu BioPharma Inc. (AYTU) reports earnings - Quartz

AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Turns Profitable: Key Portfolio Growth Drives Q2 Transformation - StockTitan

Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Galveston County Daily News

Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire

Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire

Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 - ACCESS Newswire

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire

Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - ACCESS Newswire

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - ACCESS Newswire

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - ACCESS Newswire

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - ACCESS Newswire

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results - ACCESS Newswire

Aytu BioScience Completes Acquisition of Innovus Pharmaceuticals - ACCESS Newswire

Aytu Biopharma Inc (AYTU) 財務データ

収益

当期純利益

現金流量

EPS

AYTUに似た銘柄